GoodRx Holdings, Inc.

  • Market Cap: Micro Cap
  • Industry: Computers - Software & Consulting
  • ISIN: US38246G1085
USD
2.75
0.07 (2.61%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.41 M

Shareholding (Mar 2025)

FII

8.88%

Held by 95 FIIs

DII

66.71%

Held by 28 DIIs

Promoter

6.51%

How big is GoodRx Holdings, Inc.?

22-Jun-2025

As of Jun 18, GoodRx Holdings, Inc. has a market capitalization of $1,567.97 million, with net sales of $797.41 million and a net profit of $28.44 million for the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of $724.66 million and total assets of $1,388.07 million.

As of Jun 18, GoodRx Holdings, Inc. has a market capitalization of 1,567.97 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 797.41 million and a net profit of 28.44 million for the latest four quarters ending in Mar'25, Dec'24, Sep'24, and Jun'24.<BR><BR>As of Dec'24, the balance sheet shows shareholder's funds of 724.66 million and total assets of 1,388.07 million.

Read More

What does GoodRx Holdings, Inc. do?

22-Jun-2025

GoodRx Holdings, Inc. is a holding company that offers a prescription price comparison tool, categorized as a small-cap company with a market cap of approximately $1.57 billion. As of March 2025, it reported net sales of $203 million and a net profit of $11 million.

Overview: <BR>GoodRx Holdings, Inc. is a holding company that provides a price comparison tool for prescriptions, operating within the Computers - Software & Consulting industry and categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 203 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 11 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,567.97 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 38.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.30 <BR>Return on Equity: 5.92% <BR>Price to Book: 2.40<BR><BR>Contact Details: <BR>Address: 2701 Olympic Boulevard, Suite 990, SANTA MONICA CA: 90404 <BR>Fax: 1 302 6365454

Read More

Should I buy, sell or hold GoodRx Holdings, Inc.?

22-Jun-2025

Is GoodRx Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, GoodRx Holdings, Inc. is in a bearish trend with weak strength indicators, as shown by the MACD and KST, and has significantly underperformed the S&P 500 with a 1-year return of -42.45%.

As of 8 September 2025, the technical trend for GoodRx Holdings, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a weak strength indicated by the weekly MACD and KST both showing bearish signals, along with daily moving averages confirming the bearish trend. The Bollinger Bands also reflect a bearish condition on the monthly timeframe. Additionally, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a 1-year return of -42.45% versus the S&P 500's 17.14%.

Read More

Is GoodRx Holdings, Inc. overvalued or undervalued?

25-Nov-2025

As of November 21, 2025, GoodRx Holdings, Inc. is considered very attractive in valuation, with a P/E ratio of 38, favorable EV to EBITDA ratio of 9.64, and strong ROCE and ROE metrics, indicating it is undervalued compared to peers like PropertyGuru and ZipRecruiter.

As of 21 November 2025, the valuation grade for GoodRx Holdings, Inc. has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company appears to be undervalued, particularly when considering its P/E ratio of 38, which is notably higher than the peer average of approximately 31.76 for similar companies. Additionally, the EV to EBITDA ratio stands at 9.64, which is relatively favorable compared to the industry context.<BR><BR>In terms of peer comparisons, GoodRx's P/E ratio is substantially better than that of PropertyGuru Group Ltd., which has a P/E of -132.05, and ZipRecruiter, Inc. with a P/E of -12.45. The company's ROCE of 11.40% and ROE of 5.92% further support its attractive valuation metrics. Although specific return data is not available, the lack of negative performance relative to the S&P 500 suggests that GoodRx is maintaining a competitive stance in the market.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Flat results in Jun 25

  • DEBTORS TURNOVER RATIO(HY) Lowest at 4.08 times
  • DEBT-EQUITY RATIO (HY) Highest at 41.4 %
2

With ROE of 5.92%, it has a attractive valuation with a 2.23 Price to Book Value

3

High Institutional Holdings at 87.16%

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Computers - Software & Consulting

stock-summary
Market cap

USD 1,431 Million (Micro Cap)

stock-summary
P/E

38.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.33

stock-summary
Return on Equity

7.01%

stock-summary
Price to Book

2.23

Revenue and Profits:
Net Sales:
203 Million
(Quarterly Results - Jun 2025)
Net Profit:
13 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-35.9%
0%
-35.9%
6 Months
-30.2%
0%
-30.2%
1 Year
-44.11%
0%
-44.11%
2 Years
-56.83%
0%
-56.83%
3 Years
-48.41%
0%
-48.41%
4 Years
-92.84%
0%
-92.84%
5 Years
-92.65%
0%
-92.65%

GoodRx Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.14%
EBIT Growth (5y)
-8.42%
EBIT to Interest (avg)
-1.47
Debt to EBITDA (avg)
0.43
Net Debt to Equity (avg)
0.30
Sales to Capital Employed (avg)
0.59
Tax Ratio
40.52%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
87.16%
ROCE (avg)
5.24%
ROE (avg)
2.93%
Valuation key factors
Factor
Value
P/E Ratio
38
Industry P/E
Price to Book Value
2.23
EV to EBIT
17.05
EV to EBITDA
9.64
EV to Capital Employed
1.94
EV to Sales
2.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
11.40%
ROE (Latest)
5.92%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 36 Schemes (17.85%)

Foreign Institutions

Held by 95 Foreign Institutions (8.88%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.05% vs 2.22% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 15.32% vs 65.67% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "203.10",
          "val2": "203.00",
          "chgp": "0.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "47.40",
          "val2": "49.90",
          "chgp": "-5.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "10.70",
          "val2": "10.60",
          "chgp": "0.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-5.70",
          "chgp": "84.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "12.80",
          "val2": "11.10",
          "chgp": "15.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "136.50%",
          "val2": "143.00%",
          "chgp": "-0.65%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 5.60% vs -2.13% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 284.27% vs 72.87% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "792.30",
          "val2": "750.30",
          "chgp": "5.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "158.80",
          "val2": "163.10",
          "chgp": "-2.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "52.90",
          "val2": "56.70",
          "chgp": "-6.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-25.50",
          "val2": "-77.00",
          "chgp": "66.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "16.40",
          "val2": "-8.90",
          "chgp": "284.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "112.70%",
          "val2": "68.50%",
          "chgp": "4.42%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
203.10
203.00
0.05%
Operating Profit (PBDIT) excl Other Income
47.40
49.90
-5.01%
Interest
10.70
10.60
0.94%
Exceptional Items
-0.90
-5.70
84.21%
Consolidate Net Profit
12.80
11.10
15.32%
Operating Profit Margin (Excl OI)
136.50%
143.00%
-0.65%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.05% vs 2.22% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 15.32% vs 65.67% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
792.30
750.30
5.60%
Operating Profit (PBDIT) excl Other Income
158.80
163.10
-2.64%
Interest
52.90
56.70
-6.70%
Exceptional Items
-25.50
-77.00
66.88%
Consolidate Net Profit
16.40
-8.90
284.27%
Operating Profit Margin (Excl OI)
112.70%
68.50%
4.42%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 5.60% vs -2.13% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 284.27% vs 72.87% in Dec 2023

stock-summaryCompany CV
About GoodRx Holdings, Inc. stock-summary
stock-summary
GoodRx Holdings, Inc.
Computers - Software & Consulting
GoodRx Holdings, Inc. is a holding company that provides price comparison tool for prescriptions. The Company provides GoodRx platform, which aggregates and analyzes pricing data from a number of different sources. Its platform also provides access to medication savings programs, medical provider consultations and lab tests through its telehealth offerings, HeyDoctor and the GoodRx Telehealth Marketplace, and other healthcare related content. Its prescription offering provides price comparisons and negotiated prices on prescriptions. Its subscription offerings provide consumers and their families with access to lower prescription prices on select medications in select pharmacies for a monthly or annual subscription fee. Its pharmaceutical manufacturer solutions offering provides advertising and integrated consumer affordability solutions to pharmaceutical manufacturers.
Company Coordinates stock-summary
Company Details
2701 Olympic Boulevard, Suite 990 , SANTA MONICA CA : 90404
stock-summary
Tel:
stock-summary
stock-summary
Registrar Details